GlaxoSmithKline’s experimental TB vaccine has shown that it could help prevent the disease, but further research is needed to identify patients with the strongest response.
NICE has rejected CSL Behring’s alpha1-proteinase inhibitor Respreeza for treating genetic emphysema in draft guidance, saying that it would cost a massive £8 million to give a patient a ye
